ID,Study ID,Reference,Grouping,Victim,Perpetrator,Route Victim,Route Perpetrator,Compartment,AUCR Avg,AUCR AvgType,AUCR Var,AUCR VarType,CmaxR Avg,CmaxR AvgType,CmaxR Var,CmaxR VarType,t_placebo_0,t_placebo_end,t_treatment_0,t_treatment_end,t Unit,Comment,Dose,Dose free API,Dose Unit,Route,Times of Administration,Times Unit,Comment Regimen,Administered form,Formulation type,Infusion duration [min],Water volume ingested for drug intake [mL],Comment on administration/formulation,Fasted/Fed state,Duration of fasting before drug administration [h],Duration of fasting after drug administration [h],Comment on food intake,Notghi
320,Kivistö 1997,https://www.ncbi.nlm.nih.gov/pubmed/9333111,with Perpetrator (Itraconazole),Buspirone,Itraconazole,PO,PO,Plasma,19.20,,,,13.40,,,,0,inf,79,inf,h,,100,,mg,PO,0-6-24-30-48-54-72-78,h,MD,,Sporanox,,150,,Fasted,2,3,wrt. administration of buspirone,0
318,Kivistö 1997,https://www.ncbi.nlm.nih.gov/pubmed/9333111,with Perpetrator (Erythromycin),Buspirone,Erythromycin,PO,PO,Plasma,5.9,,,,5,,,,0,inf,79,inf,h,,500,,mg,PO,0-6-14-24-30-38-48-54-62-72-78,h,MD,erythromycin base,Ery-Max 250 mg enterocapsule,,150,,Fasted,2,3,wrt. administration of buspirone,0
327,Lamberg 1998a,https://www.ncbi.nlm.nih.gov/pubmed/9923581,with Perpetrator (Fluvoxamine),Buspirone,Fluvoxamine,PO,PO,Plasma,2.35,,0.75-4.69,Range,2.01,,0.69-3.96,Range,0,inf,114,inf,h,,100,,mg,PO,0-24-48-72-96,h,SD,,Fevarin,,150,,Fasted,2,3,wrt. administration of buspirone,0
329,Lamberg 1998b,https://www.ncbi.nlm.nih.gov/pubmed/9578186,with Perpetrator (Rifampicin),Buspirone,Rifampicin,PO,PO,Plasma,0.104,,0.063-0.145,95% CI,0.163,,0.101-0.226,95% CI,0,inf,113,inf,h,,30,,mg,PO,0-24-48-72-96,h,SD,,Rimapen Orion,,150,,Fasted,2,3,wrt. administration of buspirone,0
331,Lamberg 1998c,https://www.ncbi.nlm.nih.gov/pubmed/9663178,with Perpetrator (Verapamil),Buspirone,Verapamil,PO,PO,Plasma,3.4,,,,3.4,,,,0,inf,30,inf,h,,80,,mg,PO,0-5-12-24-29,h,SD,,Verapamil tablet Orion,,150,,Fasted,2,3,wrt. administration of buspirone,0
333,Lamberg 1998c,https://www.ncbi.nlm.nih.gov/pubmed/9663178,with Perpetrator (Diltiazem),Buspirone,Diltiazem,PO,PO,Plasma,5.5,,,,4.1,,,,0,inf,30,inf,h,,60,,mg,PO,0-5-12-24-29,h,SD,,Diltiazem tablet Orion,,150,,Fasted,2,3,wrt. administration of buspirone,0
113,Chung 2006,https://www.ncbi.nlm.nih.gov/pubmed/16580903,with Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.124489796,Approx. Avg,,,0.169565217,Approx. CmaxR,,,0,inf,166,inf,h,,600,,mg,PO,"(S-0,T-24,R-9)",h,,300-mg capsules (UDL),,,,2x 300 mg capsules,,,,,0
114,Chung 2006,https://www.ncbi.nlm.nih.gov/pubmed/16580903,with Perpetrator (Ketoconazole),Midazolam,Ketoconazole,PO,PO,Plasma,9.510204082,Approx. Avg,,,2.391304348,Approx. CmaxR,,,0,inf,118,inf,h,,400,,mg,PO,"(S-0,T-24,R-10)",h,,200-mg tablets (Taro),,,,2x 200 mg tablets,,,,,0
116,Chung 2006,https://www.ncbi.nlm.nih.gov/pubmed/16580903,with Perpetrator (Rifampicin),Simvastatin,Rifampicin,PO,PO,Plasma,0.089655172,Approx. Avg,,,0.148648649,Approx. CmaxR,,,0,inf,190,inf,h,,600,,mg,PO,"(S-0,T-24,R-9)",h,,300-mg capsules (UDL),,,,2x 300 mg capsules,,,,,0
117,Chung 2006,https://www.ncbi.nlm.nih.gov/pubmed/16580903,with Perpetrator (Ketoconazole),Simvastatin,Ketoconazole,PO,PO,Plasma,12.55172414,Approx. Avg,,,7.432432432,Approx. CmaxR,,,0,inf,190,inf,h,,400,,mg,PO,"(S-0,T-24,R-10)",h,,200-mg tablets (Taro),,,,2x 200 mg tablets,,,,,0
280,Kharasch 2004,https://www.ncbi.nlm.nih.gov/pubmed/15536460,iv with Perpetrator (Rifampicin),Midazolam,Rifampicin,IV,PO,Plasma,0.521126761,Approx. Avg,,,1.009960159,Approx. CmaxR,,,0,inf,104,128,h,,600,,mg,PO,"(S-0,T-24,R-6)",h,MD OD,,,,,,,,,,0
283,Kharasch 2004,https://www.ncbi.nlm.nih.gov/pubmed/15536460,iv with Perpetrator (Rifampicin),Alfentanil,Rifampicin,IV,PO,Plasma,0.375,Approx. Avg,,,1.003325942,Approx. CmaxR,,,0,inf,105,129,h,,600,,mg,PO,"(S-0,T-24,R-6)",h,MD OD,,,,,,,,,,0
286,Kharasch 2004,https://www.ncbi.nlm.nih.gov/pubmed/15536460,po #1 with Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.052631579,Approx. Avg,,,0.10989011,Approx. CmaxR,,,0,inf,128,inf,h,,600,,mg,PO,"(S-0,T-24,R-6)",h,MD OD,,,,,,,,,,0
288,Kharasch 2004,https://www.ncbi.nlm.nih.gov/pubmed/15536460,po #1 (60 µg/kg) with Perpetrator (Rifampicin),Alfentanil,Rifampicin,PO,PO,Plasma,0.045631068,Approx. Avg,,,0.111111111,Approx. CmaxR,,,0,inf,129,inf,h,,600,,mg,PO,"(S-0,T-24,R-6)",h,MD OD,,,,,,,,,,0
392,Reitman 2011,https://www.ncbi.nlm.nih.gov/pubmed/21191377,Week 0 after Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.123,arith. mean,,,0.162,arith. mean,,,1320,inf,648,816,h,Week 4 as Control,600,,mg,PO,"(S-0,T-24,R-28)",h,,,Rifadin (2x 300mg),,,Rifadin 2x 300 mg (Merrel),Fasted,,,,0
393,Reitman 2011,https://www.ncbi.nlm.nih.gov/pubmed/21191377,Week 1 after Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.383,arith. mean,,,0.403,arith. mean,,,1320,inf,816,984,h,Week 4 as Control,600,,mg,PO,"(S-0,T-24,R-28)",h,,,Rifadin (2x 300mg),,,Rifadin 2x 300 mg (Merrel),Fasted,,,,0
394,Reitman 2011,https://www.ncbi.nlm.nih.gov/pubmed/21191377,Week 2 after Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.815,arith. mean,,,0.731,arith. mean,,,1320,inf,984,1320,h,Week 4 as Control,600,,mg,PO,"(S-0,T-24,R-28)",h,,,Rifadin (2x 300mg),,,Rifadin 2x 300 mg (Merrel),Fasted,,,,0
396,Reitman 2011,https://www.ncbi.nlm.nih.gov/pubmed/21191377,Week 0 after Perpetrator (Rifampicin),Digoxin,Rifampicin,PO,PO,Plasma,1.462,arith. mean,,,1.49,arith. mean,,,1321,inf,649,817,h,Week 4 as Control,600,,mg,PO,"(S-0,T-24,R-28)",h,,,Rifadin (2x 300mg),,,Rifadin 2x 300 mg (Merrel),Fasted,,,,0
397,Reitman 2011,https://www.ncbi.nlm.nih.gov/pubmed/21191377,Week 1 after Perpetrator (Rifampicin),Digoxin,Rifampicin,PO,PO,Plasma,0.683,arith. mean,,,69.3,arith. mean,,,1321,inf,817,985,h,Week 4 as Control,600,,mg,PO,"(S-0,T-24,R-28)",h,,,Rifadin (2x 300mg),,,Rifadin 2x 300 mg (Merrel),Fasted,,,,0
398,Reitman 2011,https://www.ncbi.nlm.nih.gov/pubmed/21191377,Week 2 after Perpetrator (Rifampicin),Digoxin,Rifampicin,PO,PO,Plasma,0.977,arith. mean,,,87.6,arith. mean,,,1321,inf,985,1321,h,Week 4 as Control,600,,mg,PO,"(S-0,T-24,R-28)",h,,,Rifadin (2x 300mg),,,Rifadin 2x 300 mg (Merrel),Fasted,,,,0
354,Markert 2013,https://www.ncbi.nlm.nih.gov/pubmed/23748747,with Perpetrator (Clarithromycin),Midazolam,Clarithromycin,0,0,Plasma,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0
469,Yeates 1996,http://www.ncbi.nlm.nih.gov/pubmed/8880291,with Perpetrator (Clarithromycin),Midazolam,Clarithromycin,PO,PO,Plasma,3.571572095,Approx. Avg,,,2.439979191,Approx. CmaxR,,,0,inf,97.5,inf,h,,250,,mg,PO,"(S-0,T-12-R-10)",h,MD BID,,Klacid tabelts,,,Kacid tablets from Abbot,Fasted,,2,,0
471,Zimmermann 1996,https://www.ncbi.nlm.nih.gov/pubmed/8720318,with Perpetrator (Erythromycin),Midazolam,Erythromycin,PO,PO,Plasma,3.813719284,Approx. Avg,,,2.711438346,Approx. CmaxR,,,0,inf,97.5,inf,h,,500,,mg,PO,"(S-0,T-8-R-15)",h,MD TID,,Zithromax,,100,Zitrhromax Pfizer,Fasted,10,3.5,,0
54,Backman 1996,https://www.ncbi.nlm.nih.gov/pubmed/8549036,with Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.041,Arith.mean,,,0.061818182,Approx. CmaxR,,,0,inf,113,inf,h,,600,,mg,PO,0-24-48-72-96,h,,,"300 mg capsules, Rimapen Orion",,,,,,,,1
56,Backman 1998,https://www.ncbi.nlm.nih.gov/pubmed/9591931,Phase IV (during Perpetrator (Rifampicin)),Midazolam,Rifampicin,PO,PO,Plasma,0.023,arith. mean,0.006,Arith. SEM,0.054,Arith. Mean,0.012,Arith. SEM,0,inf,113,185,h,,600,,mg,PO,0-24-48-72-96,h,,,"300 mg capsules, Rimapen Orion",,,,Fasted,,,,1
57,Backman 1998,https://www.ncbi.nlm.nih.gov/pubmed/9591931,Phase V (4 days after Perpetrator (Rifampicin)),Midazolam,Rifampicin,PO,PO,Plasma,0.132,arith. mean,0.028,Arith. SEM,0.202,Arith. Mean,0.042,Arith. SEM,0,inf,185,inf,h,,600,,mg,PO,0-24-48-72-96,h,,,"300 mg capsules, Rimapen Orion",,,,Fasted,,,,1
58,Backman 1998,https://www.ncbi.nlm.nih.gov/pubmed/9591931,Phase II (during Perpetrator (Itraconazole)),Midazolam,Itraconazole,PO,PO,Plasma,7.97,arith. mean,1.14,Arith. SEM,3.12,Arith. Mean,0.37,Arith. SEM,0,inf,74,170,h,,200,,mg,PO,0-24-48-72,h,,,Sporanox 100-mg capsule,,,,Fasted,,,,1
59,Backman 1998,https://www.ncbi.nlm.nih.gov/pubmed/9591931,Phase III (4 days after Perpetrator (Itraconazole)),Midazolam,Itraconazole,PO,PO,Plasma,2.63,arith. mean,0.4,Arith. SEM,1.92,Arith. Mean,0.31,Arith. SEM,0,inf,170,inf,h,,200,,mg,PO,0-24-48-72,h,,,Sporanox 100-mg capsule,,,,Fasted,,,,1
129,Eap 2004,https://www.ncbi.nlm.nih.gov/pubmed/15114429,0.075 mg with Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.441176471,Approx. Avg,,,0.225806452,Approx. Avg,,,0,inf,90,inf,h,,450,,mg,PO,"(S-0,T-24,R-5)",h,QD,,,,,,,,,,1
130,Eap 2004,https://www.ncbi.nlm.nih.gov/pubmed/15114429,0.075 mg with Perpetrator (Ketoconazole),Midazolam,Ketoconazole,PO,PO,Plasma,6.470588235,Approx. Avg,,,3.741935484,Approx. Avg,,,0,inf,48,inf,h,,200,,mg,PO,0-12-24-36,h,BID,,,,,,,,,,1
132,Eap 2004,https://www.ncbi.nlm.nih.gov/pubmed/15114429,7.5 mg with Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.052238806,Approx. Avg,,,0.111538462,Approx. Avg,,,0,inf,114,inf,h,,450,,mg,PO,"(S-0,T-24,R-5)",h,QD,,,,,,,,,,1
177,Gorski 2003,https://www.ncbi.nlm.nih.gov/pubmed/12966371,po with Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Whole Blood,0.045348837,Approx. Avg,,,0.067039106,arith. Mean,,,0,inf,132,inf,h,"from CL (L/hr/kg), Cmax dose-corrrected",600,,mg,PO,0-(S24-T24-R6),h,MD,,"pill, INN, rifampicin",,,,,,,,1
179,Gorski 2003,https://www.ncbi.nlm.nih.gov/pubmed/12966371,iv with Perpetrator (Rifampicin),Midazolam,Rifampicin,IV,PO,Whole Blood,0.458333333,Approx. Avg,,,,,,,0,inf,132,inf,h,from CL (L/hr/kg),600,,mg,PO,0-(S24-T24-R6),h,MD,,"pill, INN, rifampicin",,,,,,,,1
215,Gurley 2006,https://www.ncbi.nlm.nih.gov/pubmed/16432272,with Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.057160804,Approx. Avg,,,0.120915033,arith. Mean,,,0,inf,144,inf,h,,300,,mg,PO,"(S-0,T-12,R-14)",h,MD,Rifampin,"300mg, Rifadin®, Aventis Pharmaceuticals",,,twice daily,,,,,1
217,Gurley 2006,https://www.ncbi.nlm.nih.gov/pubmed/16432272,with Perpetrator (Clarithomycin),Midazolam,Clarithromycin,PO,PO,Plasma,8.39285714,Approx. Avg,,,3.795597484,arith. Mean,,,0,inf,144,inf,h,,500,,mg,PO,"(S-0,T-12,R-14)",h,MD,clarithromycin,"500 mg, Biaxin®, Abbott Laboratories",,,twice daily,,,,,1
221,Gurley 2008a,https://www.ncbi.nlm.nih.gov/pubmed/17495878,with Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.06031746,Approx. Avg,,,0.107623318,arith. Mean,,,0,inf,146,inf,h,,300,,mg,PO,"(S-0,T-12,R-14)",h,MD,Rifampin,"300mg, Rifadin®, Aventis Pharmaceuticals",,,twice daily,,,,,1
223,Gurley 2008a,https://www.ncbi.nlm.nih.gov/pubmed/17495878,with Perpetrator (Clarithomycin),Midazolam,Clarithromycin,PO,PO,Plasma,5.4833984,Approx. Avg,,,2.174329502,arith. Mean,,,0,inf,146,inf,h,,500,,mg,PO,"(S-0,T-12,R-14)",h,MD,clarithromycin,"500 mg, Biaxin®, Abbott Laboratories",,,twice daily,,,,,1
227,Gurley 2008b,https://www.ncbi.nlm.nih.gov/pubmed/18214850,with Perpetrator (Rifampicin),Digoxin,Rifampicin,PO,PO,Serum,0.69565217,Approx. Avg,,,0.615384615,arith. Mean,,,0,inf,144,inf,h,,300,,mg,PO,"(S-0,T-12,R-14)",h,MD,Rifampin,"Rifadin®, Aventis Pharmaceuticals",,,twice daily,,,,,1
229,Gurley 2008b,https://www.ncbi.nlm.nih.gov/pubmed/18214850,with Perpetrator (Clarithomycin),Digoxin,Clarithromycin,PO,PO,Serum,1.46575342,Approx. Avg,,,1.75,arith. Mean,,,0,inf,144,inf,h,,500,,mg,PO,"(S-0,T-12,R-14)",h,MD,clarithromycin,"Biaxin®, Abbott Laboratories",,,twice daily,,,,,1
294,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,iv with Perpetrator (Rifampicin @ 5 mg),Midazolam,Rifampicin,IV,PO,Plasma,0.84,geo. Mean,0.13,+/- 90%CI,1.03225806,arith. Mean,,,0,inf,108,inf,h,,5,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
295,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,iv with Perpetrator (Rifampicin @ 10 mg),Midazolam,Rifampicin,IV,PO,Plasma,0.77,geo. Mean,0.12,+/- 90%CI,1.064516129,arith. Mean,,,0,inf,108,inf,h,,10,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
296,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,iv with Perpetrator (Rifampicin @ 25 mg),Midazolam,Rifampicin,IV,PO,Plasma,0.63,geo. Mean,0.11,+/- 90%CI,0.838709677,arith. Mean,,,0,inf,108,inf,h,,25,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
297,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,iv with Perpetrator (Rifampicin @ 75 mg),Midazolam,Rifampicin,IV,PO,Plasma,0.6,geo. Mean,0.12,+/- 90%CI,1.322580645,arith. Mean,,,0,inf,108,inf,h,,75,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
299,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,iv with Perpetrator (Rifampicin @ 5 mg),Alfentanil,Rifampicin,IV,PO,Plasma,0.83,geo. Mean,0.16,+/- 90%CI,1.039215686,arith. Mean,,,0,inf,109,inf,h,,5,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
300,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,iv with Perpetrator (Rifampicin @ 10 mg),Alfentanil,Rifampicin,IV,PO,Plasma,0.75,geo. Mean,0.15,+/- 90%CI,1.049019608,arith. Mean,,,0,inf,109,inf,h,,10,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
301,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,iv with Perpetrator (Rifampicin @ 25 mg),Alfentanil,Rifampicin,IV,PO,Plasma,0.59,geo. Mean,0.12,+/- 90%CI,1,arith. Mean,,,0,inf,109,inf,h,,25,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
302,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,iv with Perpetrator (Rifampicin @ 75 mg),Alfentanil,Rifampicin,IV,PO,Plasma,0.51,geo. Mean,0.12,+/- 90%CI,1.029411765,arith. Mean,,,0,inf,109,inf,h,,75,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
304,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,po with Perpetrator (Rifampicin @ 5 mg),Midazolam,Rifampicin,PO,PO,Plasma,0.8,geo. Mean,0.19,+/- 90%CI,0.8,arith. Mean,,,0,inf,132,inf,h,,5,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
305,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,po with Perpetrator (Rifampicin @ 10 mg),Midazolam,Rifampicin,PO,PO,Plasma,0.68,geo. Mean,0.17,+/- 90%CI,0.93333333,arith. Mean,,,0,inf,132,inf,h,,10,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
306,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,po with Perpetrator (Rifampicin @ 25 mg),Midazolam,Rifampicin,PO,PO,Plasma,0.4,geo. Mean,0.1,+/- 90%CI,0.506666667,arith. Mean,,,0,inf,132,inf,h,,25,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
307,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,po with Perpetrator (Rifampicin @ 75 mg),Midazolam,Rifampicin,PO,PO,Plasma,0.25,geo. Mean,0.09,+/- 90%CI,0.34,arith. Mean,,,0,inf,132,inf,h,,75,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
309,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,po with Perpetrator (Rifampicin @ 5 mg),Alfentanil,Rifampicin,PO,PO,Plasma,0.74,geo. Mean,0.16,+/- 90%CI,0.862745098,arith. Mean,,,0,inf,133,inf,h,,5,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
310,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,po with Perpetrator (Rifampicin @ 10 mg),Alfentanil,Rifampicin,PO,PO,Plasma,0.61,geo. Mean,0.23,+/- 90%CI,0.862745098,arith. Mean,,,0,inf,133,inf,h,,10,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
311,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,po with Perpetrator (Rifampicin @ 25 mg),Alfentanil,Rifampicin,PO,PO,Plasma,0.3,geo. Mean,0.1,+/- 90%CI,0.490196078,arith. Mean,,,0,inf,133,inf,h,,25,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
312,Kharasch 2011,https://www.ncbi.nlm.nih.gov/pubmed/21562488,po with Perpetrator (Rifampicin @ 75 mg),Alfentanil,Rifampicin,PO,PO,Plasma,0.13,geo. Mean,0.06,+/- 90%CI,0.254901961,arith. Mean,,,0,inf,133,inf,h,,75,,mg,PO,0-24-48-72-96-120,h,MD,rifampin,capsules,,,at bedtime,,,,,1
342,Link 2008,https://www.ncbi.nlm.nih.gov/pubmed/18537963,iv with Perpetrator (Rifampicin),Midazolam,Rifampicin,IV,PO,Plasma,0.655007949,Approx. Median,,,1.105960265,Approx. Median,,,0,inf,144,inf,h,,600,,mg,PO,0-24-48-72-96-120,h,MD,rifampicin,"Rimactan®, 600 mg coated tablet, Medika AG,",,,in the morning,,,,,1
344,Link 2008,https://www.ncbi.nlm.nih.gov/pubmed/18537963,po with Perpetrator (Rifampicin),Midazolam,Rifampicin,PO,PO,Plasma,0.015549077,Approx. Median,,,0.034865293,Approx. Median,,,0,inf,144,inf,h,,600,,mg,PO,0-24-48-72-96-120,h,MD,rifampicin,"Rimactan®, 600 mg coated tablet, Medika AG,",,,in the morning,,,,,1
391,Phimmasone 2001,https://www.ncbi.nlm.nih.gov/pubmed/11753266,with Perpetrator (Rifampicin),Alfentanil,Rifampicin,IV,PO,Plasma,0.55,arith. mean,,,,,,,0,inf,107,inf,h,,600,,mg,PO,0-24-48-72-96,h,MD,rifampin,,,,in the evening,,,,,1
389,Phimmasone 2001,https://www.ncbi.nlm.nih.gov/pubmed/11753266,with Perpetrator (Rifampicin),Midazolam,Rifampicin,IV,PO,Plasma,0.51,arith. mean,,,,,,,0,inf,106,inf,h,,600,,mg,PO,0-24-48-72-96,h,MD,rifampin,,,,in the evening,,,,,1
422,Szalat 2007,https://www.ncbi.nlm.nih.gov/pubmed/17553741,with Perpetrator (Rifampicin),Midazolam,Rifampicin,IV,PO,Plasma,0.579467114,Approx. Avg,,,,,,,0,inf,132,inf,h,,600,,mg,PO,0-24-48-72-96-120-144,h,MD,rifampicin,rifampicin (Sandoz GmbH),,,,,,,,1
191,Greiner 1999,https://www.ncbi.nlm.nih.gov/pubmed/10411543,po with Perpetrator (Rifampicin),Digoxin,Rifampicin,PO,PO,Plasma,0.697080292,Approx. Avg,,,0.481481481,Approx. Avg,,,0,inf,240,inf,h,,600,,mg,PO,0-(S24-T24-R15),h,MD,rifampin,RIFA; Grünenthal GmbH,,,,,,,,1
193,Greiner 1999,https://www.ncbi.nlm.nih.gov/pubmed/10411543,iv with Perpetrator (Rifampicin),Digoxin,Rifampicin,IV,PO,Plasma,0.853379152,Approx. Avg,,,0.834008097,Approx. Avg,,,0,inf,240,inf,h,,600,,mg,PO,0-(S24-T24-R15),h,MD,rifampin,RIFA; Grünenthal GmbH,,,,,,,,1
337,Larsen 2007,https://www.ncbi.nlm.nih.gov/pubmed/17365992,with Perpetrator (Rifampicin),Digoxin,Rifampicin,PO,0,Serum,0.817346939,Approx. Avg,,,,,,,0,inf,144,inf,h,,600,,mg,,0-24-48-72-96-120,h,MD,,,,,,,,,,1
338,Larsen 2007,https://www.ncbi.nlm.nih.gov/pubmed/17365992,with Perpetrator (Ketoconazole),Digoxin,Ketoconazole,PO,0,Serum,1.091836735,Approx. Avg,,,,,,,0,inf,96,inf,h,,200,,mg,,0-24-48-72,h,MD,,,,,,,,,,1
314,Kirby 2012,https://www.ncbi.nlm.nih.gov/pubmed/22190694,Study 1 - Staggered Administration with RIF,Digoxin,Rifampicin,PO,PO,Plasma,0.81,geo. Mean,,,0.78,geo. Mean,,,0,inf,324,inf,h,,600,,mg,PO,(S0-T24-R14),h,QD,rifampin,300-mg capsules; Novartis,,,,,,,,1
316,Kirby 2012,https://www.ncbi.nlm.nih.gov/pubmed/22190694,Study 2 - Simultaneous Administration with RIF,Digoxin,Rifampicin,PO,PO,Plasma,1.25,geo. Mean,,,1.55,geo. Mean,,,0,inf,360,inf,h,,600,,mg,PO,(S0-T24-R14),h,QD,rifampin,300-mg capsules; Novartis,,,,,,,,1
271,Jalava 1997,https://www.ncbi.nlm.nih.gov/pubmed/9421099,po with Perpetrator (Itraconazole),Digoxin,Itraconazole,PO,PO,Serum,168,arith. Mean,,,134,arith. Mean,,,0,inf,49,inf,h,,200,,mg,,0-24-48-72-96,,,,"Sporanox 100-mg caps, Janssen Pharmaceuticals, Beerse, Belgium",,120,,,,,,
173,Gorski 1998,https://www.ncbi.nlm.nih.gov/pubmed/9728893,po with Perpetrator (Clarithromycin),Midazolam,Clarithromycin,PO,PO,Whole Blood,7.142857143,Approx. Avg,,,,,,,0,inf,146,inf,h,from CL (L/hr/kg),500,,mg,PO,0-(S12-T-12-R13),h,MD,,pill,,,,,,,,1
175,Gorski 1998,https://www.ncbi.nlm.nih.gov/pubmed/9728893,iv with Perpetrator (Clarithromycin),Midazolam,Clarithromycin,IV,PO,Whole Blood,2.666666667,Approx. Avg,,,,,,,0,inf,146,inf,h,from CL (L/hr/kg),500,,mg,PO,0-(S12-T-12-R13),h,MD,,pill,,,,,,,,1
276,Kharasch 1997,https://www.ncbi.nlm.nih.gov/pubmed/9232132,with Perpetrator (Rifampicin),Midazolam,Rifampicin,IV,PO,Plasma,0.379310345,Approx. Avg,,,,,,,0,inf,120,inf,h,AUCR estimated from CL ratio,600,,mg,PO,0-24-48-72-96,h,MD,,,,,,,,,,1
278,Kharasch 1997,https://www.ncbi.nlm.nih.gov/pubmed/9232132,with Perpetrator (Rifampicin),Alfentanil,Rifampicin,IV,PO,Plasma,0.363013699,Approx. Avg,,,,,,,0,inf,120.5,inf,h,AUCR estimated from CL ratio,600,,mg,PO,0-24-48-72-96,h,MD,,,,,,,,,,1
377,Olkkola 1996,https://www.ncbi.nlm.nih.gov/pubmed/8623953,day 1 (po) with Perpetrator (Itraconazole),Midazolam,Itraconazole,PO,PO,Plasma,3.4,arith. mean,,,1.8,arith. Mean,,,0,inf,2,inf,h,,200,,mg,PO,0,h,SD,,,,,,,,,,1
378,Olkkola 1996,https://www.ncbi.nlm.nih.gov/pubmed/8623953,day 4 (iv) with Perpetrator (Itraconazole),Midazolam,Itraconazole,IV,PO,Plasma,3.225806452,Approx. Avg,,,,,,,0,inf,74,inf,h,,200,,mg,PO,0-24-48-72,h,MD,,,,,,,,,,1
379,Olkkola 1996,https://www.ncbi.nlm.nih.gov/pubmed/8623953,day 6 (po) with Perpetrator (Itraconazole),Midazolam,Itraconazole,PO,PO,Plasma,6.6,arith. mean,,,2.5,arith. Mean,,,0,inf,122,inf,h,,200,,mg,PO,0-24-48-72-96-120,h,MD,,,,,,,,,,1
380,Olkkola 1996,https://www.ncbi.nlm.nih.gov/pubmed/8623953,day 1 (po) with Perpetrator (Fluconazole),Midazolam,Fluconazole,PO,PO,Plasma,2.5,arith. mean,,,2.5,arith. Mean,,,0,inf,2,inf,h,,400,,mg,PO,0,h,MD,,,,,,,,,,1
381,Olkkola 1996,https://www.ncbi.nlm.nih.gov/pubmed/8623953,day 4 (iv) with Perpetrator (Fluconazole),Midazolam,Fluconazole,IV,PO,Plasma,2.040816327,Approx. Avg,,,,,,,0,inf,74,inf,h,,400/200,,mg,PO,400: 0; 200: 24-48-72,h,MD,,,,,,,,,,1
382,Olkkola 1996,https://www.ncbi.nlm.nih.gov/pubmed/8623953,day 6 (po) with Perpetrator (Fluconazole),Midazolam,Fluconazole,PO,PO,Plasma,3.6,arith. mean,,,1.7,arith. Mean,,,0,inf,122,inf,h,,400/200,,mg,PO,400: 0; 200: 24-48-72-96-120,h,MD,,,,,,,,,,1
370,Olkkola 1994,https://www.ncbi.nlm.nih.gov/pubmed/8181191,po with Perpetrator (Itraconazole),Midazolam,Itraconazole,PO,PO,Plasma,10.8,arith. mean,,,3.4,arith. Mean,,,0,inf,73,inf,h,,200,,mg,PO,0-24-48-72,h,MD,itraconazole,"Sporanox, Orion",,,,Fasted,2,5,,1
371,Olkkola 1994,https://www.ncbi.nlm.nih.gov/pubmed/8181191,po with Perpetrator (Ketoconazole,Midazolam,Ketoconazole,PO,PO,Plasma,15.9,arith. mean,,,4.1,arith. Mean,,,0,inf,73,inf,h,,400,,mg,PO,0-24-48-72,h,MD,ketoconazole,"Nizoral, Orion",,,,Fasted,2,5,,1
366,Olkkola 1993,https://www.ncbi.nlm.nih.gov/pubmed/8453848,po with Perpetrator (Erythromycin),Midazolam,Erythromycin,PO,PO,Plasma,4.416666667,Approx. Avg,,,2.7,Approx. Avg,,,0,inf,128,inf,h,,500,,mg,PO,(S0-T8-R16)-126-136-144-152-160,h,three times a day,erythromycin base,"Etromycin, 500 mg enterotablet, Orion Pharmaceutical Company Ltd.",,200,,,,,,1
368,Olkkola 1993,https://www.ncbi.nlm.nih.gov/pubmed/8453848,iv with Perpetrator (Erythromycin),Midazolam,Erythromycin,IV,PO,Plasma,2.166666667,Approx. Avg,,,,,,,0,inf,128,inf,h,,500,,mg,PO,(S0-T8-R16)-126-136-144-152-160,h,three times a day,erythromycin base,"Etromycin, 500 mg enterotablet, Orion Pharmaceutical Company Ltd.",,200,,,,,,1
401,Saari 2006,https://www.ncbi.nlm.nih.gov/pubmed/16580904,po with Perpetrator (Voriconazole),Midazolam,Voriconazole,PO,PO,Plasma,9.85,geo. Mean,8.23-11.79,90% CI,3.56,geo. Mean,2.85-4.44,90% CI,0,inf,37,inf,h,,400/200,,mg,PO,400mg: 0-12; 200mg: 24-36,h,MD,voriconazole,Vfend tablet; Pfizer,,150,The last dose of voriconazole was given at 8 AM with 150 mL of water,Fasted,11,5,,1
404,Saari 2006,https://www.ncbi.nlm.nih.gov/pubmed/16580904,iv with Perpetrator (Voriconazole),Midazolam,Voriconazole,IV,PO,Plasma,3.61,geo. Mean,3.20-4.08,90% CI,,,,,0,inf,37,inf,h,,400/200,,mg,PO,400mg: 0-12; 200mg: 24-36,h,MD,voriconazole,Vfend tablet; Pfizer,,150,The last dose of voriconazole was given at 8 AM with 150 mL of water,Fasted,11,5,,1
420,Swart 2002,https://www.ncbi.nlm.nih.gov/pubmed/11851636 ,day 10 Control with Perpetrator (Erythromycin),Midazolam,Erythromycin,IV,PO,Plasma,1.52,Approx. Avg,,,,,,,0,inf,96,inf,h,"according to the methods section, AUC was calculated, but data are not given in text or tables.",500,,mg,PO,0-(S0-T6-R20),h,"erythromycin was taken 4 times per day, but timing was not specified. A fixed dose interval oh tau=6h was assumed. Midazolam and lignocaine were co-administered with erythromycin.",,Capsule,,200,2x 100-mg itraconazole capsules with coated sugar spheres,,,,,1
362,Okudaira 2007,https://www.ncbi.nlm.nih.gov/pubmed/17585116,EM 2 with Perpetrator (Erythromycin),Midazolam,Erythromycin,PO,PO,Plasma,2.32,arith. mean,0.9,arith. SD,1.818181818,Approx. Avg,,,0,inf,25,73,h,,200,,mg,PO,0-5-10.5-15-24-29-34.5-39,h,MD,erythromycin,Erythrocin; Dainippon Pharmaceutical Co,,150,,Fed,,,standardized light breakfast at 07:20am,1
363,Okudaira 2007,https://www.ncbi.nlm.nih.gov/pubmed/17585116,EM 4 with Perpetrator (Erythromycin),Midazolam,Erythromycin,PO,PO,Plasma,3.38,arith. mean,1.6,arith. SD,2.4,Approx. Avg,,,0,inf,73,145,h,,200,,mg,PO,0-5-10.5-15-24-29-34.5-39-48-53-58.5-63-72-77-82.5-87,h,MD,erythromycin,Erythrocin; Dainippon Pharmaceutical Co,,150,,Fed,,,standardized light breakfast at 07:20am,1
364,Okudaira 2007,https://www.ncbi.nlm.nih.gov/pubmed/17585116,EM 7 with Perpetrator (Erythromycin),Midazolam,Erythromycin,PO,PO,Plasma,3.38,arith. mean,1.4,arith. SD,2.345454545,Approx. Avg,,,0,inf,145,inf,h,,200,,mg,PO,0-5-10.5-15-24-29-34.5-39-48-53-58.5-63-72-77-82.5-87-96-101-106.5-111-120-125-130.5-135-144-149-154.5-159,h,MD,erythromycin,Erythrocin; Dainippon Pharmaceutical Co,,150,,Fed,,,standardized light breakfast at 07:20am,1
424,Templeton 2010,https://www.ncbi.nlm.nih.gov/pubmed/20739919,with Perpetrator (Itraconazole @ 50 mg),Midazolam,Itraconazole,PO,PO,Plasma,2,arith. Mean,0.6,arith. SD,,,,,0,inf,4,inf,h,,50,,mg,PO,0,h,SD,,Oral solution,,,,Fasted,,0.5,wrt. administration of midazolam,1
425,Templeton 2010,https://www.ncbi.nlm.nih.gov/pubmed/20739919,with Perpetrator (Itraconazole @ 200 mg),Midazolam,Itraconazole,PO,PO,Plasma,4.7,arith. Mean,1.4,arith. SD,,,,,0,inf,4,inf,h,,200,,mg,PO,0,h,SD,,Oral solution,,,,Fasted,,0.5,wrt. administration of midazolam,1
426,Templeton 2010,https://www.ncbi.nlm.nih.gov/pubmed/20739919,with Perpetrator (Itraconazole @ 400 mg),Midazolam,Itraconazole,PO,PO,Plasma,5.4,arith. Mean,1.5,arith. SD,,,,,0,inf,4,inf,h,,400,,mg,PO,0,h,SD,,Oral solution,,,,Fasted,,0.5,wrt. administration of midazolam,1
428,Tham 2006,https://www.ncbi.nlm.nih.gov/pubmed/16628140,with Perpetrator (Ketoconazole 50 mg),Midazolam,Ketoconazole,IV,PO,Plasma,1.588235294,Approx. Avg,,,,,,,0,inf,47,inf,h,,200,,mg,PO,0-12-24-36-48-60,h,MD,ketoconazole,Janssen Cilag,,,at 8am and 8pm,,,,,1
50,Ahonen 1995,http://www.ncbi.nlm.nih.gov/pubmed/8527290,with Perpetrator (Itraconazole),Midazolam,Itraconazole,PO,PO,Plasma,5.745098039,Approx. Avg,,,2.558823529,Approx. Avg,,,0,inf,74,inf,h,,100,,mg,PO,"(S-0,T-24,R-4)",h,OD,,Sporanox,,,Sporanox Janssen,,,,,1
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
